- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06991244
- Original Trial
EMDR 2.0 Group Therapy for PTSD, Depression, and Anxiety in Earthquake Survivors (EQ-EMDR20)
The Effectiveness of EMDR 2.0 Group Intervention on Post-Traumatic Stress, Depression, and Anxiety Symptoms in Earthquake Survivors
The objective of this clinical study was to examine whether a brief EMDR 2.0 group intervention could reduce symptoms of post-traumatic stress disorder (PTSD), depression, and anxiety in adult survivors of the 2023 Türkiye earthquake. The study was conducted face-to-face in a container city in Malatya, one of the regions most severely affected by the disaster. EMDR 2.0 is an enhanced version of standard EMDR therapy that uses working memory taxation techniques to accelerate emotional processing.
The primary research questions included whether EMDR 2.0 group therapy reduces PTSD symptoms in earthquake survivors, and whether it helps decrease symptoms of depression and anxiety.
Participants attended three EMDR 2.0 group sessions in person over the course of one week and completed psychological assessments before the intervention, one week after, and one month after. Verbal disclosure of traumatic memories was not required during the sessions. Researchers used self-report questionnaires to evaluate changes in trauma-related distress, depression, and anxiety. This study contributes to the development of fast, accessible, and field-based psychological support strategies for communities affected by disasters.
Study Overview
Status
Intervention / Treatment
Detailed Description
Following the 2023 Türkiye earthquakes, widespread displacement, loss, and psychological trauma created an urgent need for effective and accessible mental health interventions. This clinical study was developed to address that need by offering a rapid, structured group therapy protocol-EMDR 2.0-to adult survivors residing in a temporary container city in Malatya, a region significantly impacted by the disaster.
EMDR 2.0 is a modified version of traditional Eye Movement Desensitization and Reprocessing therapy. It intensifies working memory taxation through structured, dual-attention tasks and allows for the safe and efficient processing of traumatic memories without requiring verbal disclosure.
The intervention was delivered in the same container units used as temporary housing by survivors, thereby transforming these living spaces into short-term therapeutic settings. Over the course of one week, three group sessions were administered in person. While participants were gathered in a group format, each individual engaged in processing their own traumatic imagery using the EMDR 2.0 protocol.
This approach provided containment and emotional safety within a physically and psychologically shared post-disaster context. Verbal expression of trauma was not required, which minimized the risk of retraumatization and enhanced the accessibility of the intervention for individuals hesitant to disclose.
The study was designed not only to evaluate the effectiveness of EMDR 2.0 in reducing symptoms of PTSD, depression, and anxiety but also to assess the feasibility of implementing this method under real-world post-disaster conditions with limited resources. The findings contribute to the growing body of knowledge on scalable trauma interventions suitable for use in field-based, high-need humanitarian settings.
This work underscores the potential of brief, structured group interventions to facilitate emotional recovery when survivors are supported in environments that respect both their privacy and collective experience.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Malatya
-
Battalgazi, Malatya, Turkey, 44000
- Malatya Teknokent Container Settlement
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or older
- Being a survivor of the 2023 Türkiye earthquakes
- Currently residing in a temporary container settlement in Malatya
- Ability to attend all three face-to-face intervention sessions
- Ability to provide informed consent
- Sufficient cognitive and emotional capacity to complete self-report questionnaires
- Basic literacy (reading and writing) in Turkish to understand and complete self-report scales
- Willingness to voluntarily participate in the study
Exclusion Criteria:
- Having a current diagnosis of a psychotic disorder (e.g., schizophrenia, bipolar disorder with psychotic features)
- History of severe head trauma or neurological condition affecting cognitive capacity
- Active suicidal ideation or risk requiring emergency psychiatric care
- Ongoing substance dependence
- Receiving concurrent trauma-focused psychotherapy during the study period
- Significant hearing, vision, or language impairment interfering with participation
- Inability to attend scheduled sessions or complete follow-up assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: EMDR 2.0 Group
Participants in this group received a face-to-face EMDR 2.0 group intervention delivered over three sessions in a container city setting in Malatya, Türkiye, following the 2023 earthquake.
|
A short-term trauma-focused group protocol adapted from EMDR 2.0, delivered in three sessions over one week, targeting PTSD, depression, and anxiety symptoms among earthquake survivors.
The first session lasted 90 minutes, followed by two 60-minute sessions.
The intervention was administered face-to-face in a container city in Malatya, Türkiye.
All sessions were conducted by a certified EMDR therapist who had completed advanced EMDR 2.0 training.
|
|
No Intervention: Control Group
Participants in this group did not receive any psychological intervention during the study period but completed the same assessments as the intervention group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PTSD symptom severity
Time Frame: Assessed at three time points - before the intervention (Day 0), one week after the completion of the third session (approximately Day 7), and one month after the completion (approximately Day 30)
|
The primary outcome is the change in PTSD symptoms as measured by the PCL-5, a 20-item self-report questionnaire that assesses PTSD symptoms based on DSM-5 criteria.
The scale includes four subscales: intrusion, avoidance, negative alterations in cognition and mood, and alterations in arousal and reactivity.
Higher scores indicate greater symptom severity.
|
Assessed at three time points - before the intervention (Day 0), one week after the completion of the third session (approximately Day 7), and one month after the completion (approximately Day 30)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depression symptom severity (DASS-21 Depression subscale)
Time Frame: Assessed at three time points: before the intervention (Day 0), one week after completion of the third session (approximately Day 7), and one month after completion (approximately Day 30)
|
The DASS-21 Depression subscale evaluates core symptoms such as dysphoria, hopelessness, and devaluation of life.
Higher scores indicate more severe depressive symptoms.
|
Assessed at three time points: before the intervention (Day 0), one week after completion of the third session (approximately Day 7), and one month after completion (approximately Day 30)
|
|
Anxiety symptom severity (DASS-21 Anxiety subscale)
Time Frame: Assessed at three time points: before the intervention (Day 0), one week after completion of the third session (approximately Day 7), and one month after completion (approximately Day 30)
|
The DASS-21 Anxiety subscale measures autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect.
|
Assessed at three time points: before the intervention (Day 0), one week after completion of the third session (approximately Day 7), and one month after completion (approximately Day 30)
|
|
Stress symptom severity (DASS-21 Stress subscale)
Time Frame: Assessed at three time points: before the intervention (Day 0), one week after completion of the third session (approximately Day 7), and one month after completion (approximately Day 30).
|
The DASS-21 Stress subscale evaluates persistent tension, irritability, and difficulty relaxing.
Higher scores indicate elevated stress-related symptoms.
|
Assessed at three time points: before the intervention (Day 0), one week after completion of the third session (approximately Day 7), and one month after completion (approximately Day 30).
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Alisan B Yasar, MD AssocProf, Istanbul Gelisim University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KINIK EMDR 2.0 EQ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
Clinical Trials on EMDR 2.0 Group Protocol
-
Academy of Therapeutic Sciences, TurkeyCompletedPost Traumatic Stress DisorderTurkey
-
Ciclo de MutaçãoSao Jose do Rio Preto Medical SchoolCompleted
-
Mersin UniversityCompleted
-
University of PisaCompletedCognitive Change | Child, Only | Distress, Emotional | Narration | Memory DysfunctionItaly
-
Centre Hospitalier René DubosTerminated
-
Vanderbilt University Medical CenterCompletedHIV Infected IndividualsUnited States
-
BrainQ Technologies Ltd.Completed
-
Dominique JANUELRecruiting
-
Huazhong University of Science and TechnologyWuhan Union Hospital, China; Wuhan No.1 Hospital; The Affiliated Hospital of... and other collaboratorsRecruitingDiminished Ovarian ReserveChina
-
Riphah International UniversityCompletedSports Physical TherapyPakistan